Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2025

Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Second vote and conclusions/discussion

Date

26 Mar 2025

Session

Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Topics

Cytotoxic Therapy;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Paul van Schil

Authors

P.E. van Schil

Author affiliations

  • UZA - University Hospital Antwerp, Edegem/BE

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction and first vote

Presenter: Paul van Schil

Session: Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Resources:

Slides

Webcast

Pros

Presenter: Leah Backhus

Session: Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Resources:

Slides

Webcast

Cons

Presenter: Nan Wu

Session: Invasive mediastinal re-staging after Chemo-IO neoadjuvant therapy: Pros and cons

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.